Clinical Trial Update: Long-Term Safety Follow-up Study of Cysteamine Bitartrate Delayed-release Capsules (RP103) [Phase 3]

View source ↗

Summary

Phase 3 long-term safety follow-up of cysteamine bitartrate delayed-release capsules (RP103) in cystinosis has been completed, with results posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cystinosis

Drugs mentioned

• Cysteamine Bitartrate Delayed-release Capsules (cysteamine bitartrate, delayed-release)

Snippet

Sponsor: Amgen | Conditions: Cystinosis | Phase 3 | Status: COMPLETED | Results posted: 2018-07-24